Hepatitis B Prophylaxis Outcomes in Patients Receiving Immunosuppressive Therapy: A Retrospective Cohort Study
Öz
Background: Hepatitis B virus (HBV) reactivation is a critical complication for patients undergoing immunosuppressive therapy. This study aimed to evaluate the clinical outcomes of HBV screening, prophylaxis strategies, and the incidence of reactivation in patients receiving immunosuppressive regimens.
Methods: We conducted a retrospective study at Gazi University Faculty of Medicine involving 90 patients with HBV infection who were candidates for immunosuppressive therapy between January 2010 and December 2017. Demographic characteristics, viral serology (HBsAg, anti-HBs, anti-HBc, HBeAg, anti-HBe, and HBV-DNA levels), types of underlying diseases, and antiviral prophylaxis protocols were analyzed. Reactivation was defined based on virological and biochemical parameters during follow-up.
Results: The study included 90 patients (mean age 53.57 ± 6.3 years; 46.7% female). The primary indications for immunosuppression were oncological diseases (n=55, 61.1%), followed by rheumatologic disorders (18.9%). Among the oncology subgroup, 31 of 55 patients (56.4%) were HBsAg positive, accounting for 31 of the 49 HBsAg-positive patients in the overall cohort. Of 55 patients with adequate follow-up, HBV reactivation was detected in 5 (9.1%). Significant differences were observed in ALT and AST levels based on HBsAg positivity (p=0.036 and p=0.021, respectively). Among followed patients, no reactivation occurred in the lamivudine group (0/11), while reactivation was observed in tenofovir (2/22), entecavir (1/14), and sequential lamivudine-tenofovir groups (2/8). The highest reactivation rate was observed in patients with delayed prophylaxis initiation.
Conclusions: Pre-treatment screening for HBV is essential to identify at-risk patients. Timely initiation of potent antiviral prophylaxis significantly reduces reactivation rates and associated hepatic complications in immunocompromised patients.
Anahtar Kelimeler
Hepatitis B virus, Antiviral Prophylaxis, Immunosuppressive Agents, Virus Reactivation, Medical Oncology
Destekleyen Kurum
The authors received no financial support for the research, authorship, and/or publication of this article..
Etik Beyan
This study was approved by the Gazi University Ethics Commission (Date: 25.07.2017, Decision No: 07, Research Code: 2017-356). Due to the retrospective nature of the study, the requirement for informed consent was waived by the ethics committee. The study was conducted in accordance with the Declaration of Helsinki.
Teşekkür
The authors would like to thank the staff of Gazi University Faculty of Medicine, Department of Internal Medicine, for their support during the data collection process.
Kaynakça
- Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.Jhep. October 2006;45(4):529-38. doi:10.1016/j.jhep.2006.05.013
- Liang TJ. Hepatitis B: the virus and disease. Hepatology. May 2009;49(5 Suppl):S13-21. doi:10.1002/hep.22881
- Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology. September 2006;44(3):694-702. doi:10.1002/hep.21299
- Vutien P, Nguyen MH. HBV Reactivation in Immunosuppressed Patients: Screening, Prevention, and Management Including Solid Organ Transplant Recipients. Viruses. 09 March 2025;17(3):388. doi:10.3390/v17030388
- Cohen EB, Regev A, Garg A, Di Bisceglie AM, Lewis JH, Vierling JM, et al. Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy. Drug Saf. April 2024;47(4):321-32. doi:10.1007/s40264-024-01399-4
- Yılmaz Nakir İ, Çağlar B, Zerdali E, Karaduman RG, Pehlivanoğlu F. Real-World Effectiveness of Antiviral Prophylaxis for Preventing Hepatitis B Virus (HBV) Reactivation in Patients Undergoing Immunosuppressive Therapy. Viruses. 29 October 2025;17(11):1436. doi:10.3390/v17111436
- Zou X, Guo L, Gu Y, Yang Z, Huang P, Liu T, et al. Optimal timing of antiviral therapy for patients with malignant tumor who presented with hepatitis B reactivation during chemotherapy and/or immunosuppressive therapy. J Cancer. 2020;11(12):3559-66. doi:10.7150/jca.40154
- Zhao Y, Song Y, Zhang H, Qu T, Axinbai M, Yang Y, et al. Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis. Front Oncol. 16 January 2023;12:1050714. doi:10.3389/fonc.2022.1050714
- Abd El Aziz MA, Sacco R, Facciorusso A. Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review. Antivir Chem Chemother. 2020;28:2040206620921331. doi:10.1177/2040206620921331
- Smalls DJ, Kiger RE, Norris LB, Bennett CL, Love BL. Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies. Pharmacotherapy. December 2019;39(12):1190-203. doi:10.1002/phar.2340